SCHEMBL7023673

SCHEMBL7023673

Nc1cc(Br)c(Cl)cc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
GLA P06280 1/20 0.50
ALDH1A1 P00352 4/20 0.47
POLB P06746 3/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP3A4 P08684 1/20 0.46
IDO1 P14902 1/20 0.46
KMT2A Q03164 2/20 0.44
GFER P55789 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MAPT P10636 2/20 0.42
MCL1 Q07820 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
THRB P10828 1/20 0.42
PKM P14618 1/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30077664 1.00 KDM4E (0.50) KDM4EGLAALDH1A1POLBGAA
SCHEMBL30626196 1.00 KDM4E (0.50) KDM4EGLAALDH1A1POLBGAA
SCHEMBL27650666 0.92 KDM4E (0.50) KDM4EGLAALDH1A1POLBGAA
SCHEMBL856256 0.92 KDM4E (0.50) KDM4EGLAALDH1A1POLBGAA
SCHEMBL16117986 0.84 SLC9A1 (0.44) ALDH1A1POLBGAAHPGDL3MBTL1
SCHEMBL1047232 0.83 KDM4E (0.57) KDM4EGLAALDH1A1POLBGAA
SCHEMBL3031603 0.83 CYP3A4 (0.52) KDM4EGLAALDH1A1POLBGAA
SCHEMBL16636823 0.82 SLC9A1 (0.40) KDM4EGLAALDH1A1POLBGAA
SCHEMBL30390446 0.82 SLC9A1 (0.40) KDM4EGLAALDH1A1POLBGAA
SCHEMBL23783264 0.81 CA12 (0.50) KDM4EALDH1A1POLBHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117466759-A Preparation method of 2-amino-4-bromo-5-chlorobenzoic acid 阜新清稷升科技有限公司 2024-01-30 CN claimed
CN-116854603-A Preparation method of medical intermediate compound 2-amino-4-bromo-5-chlorobenzoic acid 沈阳感光化工研究院有限公司 2023-10-10 CN claimed
CN-110759831-B Method for preparing halofuginone intermediate 2-amino-4-bromo-5-chlorobenzoic acid 浙江金伯士药业有限公司 2022-09-27 CN claimed
CN-112409272-A Preparation method and application of 6-chloro-7-bromo-4 (3H) -quinazolinone 河北美荷药业有限公司 2021-02-26 CN claimed
CN-110759831-A Method for preparing halofuginone intermediate 2-amino-4-bromo-5-chlorobenzoic acid 浙江金伯士药业有限公司 2020-02-07 CN claimed
US-5744638-A Process for the preparation of haloanthranilic acids RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) 1998-04-28 US claimed
US-12473291-B2 Benzodiazepine compound, preparation method therefor, and use thereof in medicine WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) 2025-11-18 US disclosed
CN-112409272-B Preparation method and application of 6-chloro-7-bromo-4 (3H) -quinazolinone 河北美荷药业有限公司 2025-09-16 CN disclosed
CN-117466759-B Preparation method of 2-amino-4-bromo-5-chlorobenzoic acid 阜新清稷升科技有限公司 2025-07-25 CN disclosed
CN-117466759-B Preparation method of 2-amino-4-bromo-5-chlorobenzoic acid 阜新清稷升科技有限公司 2025-07-25 CN disclosed
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-06-12 US disclosed
EP-4548918-A2 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2025-05-07 EP disclosed
US-20250122212-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
US-5981749-A Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-11-09 US disclosed
US-5973145-A Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-10-26 US disclosed
US-5795984-A Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1998-08-18 US disclosed
US-5744638-A Process for the preparation of haloanthranilic acids RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) 1998-04-28 US disclosed
EP-0781767-A1 Process for producing isatoic anhydrides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-07-02 EP disclosed
EP-0551632-B1 Process for the preparation of halogenoanthranilic acid RIEDEL DE HAEN AG (DE) 1996-06-26 EP disclosed
EP-0551632-A2 Process for the preparation of halogenoanthranilic acid RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) 1993-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS KDM4E 4221/4885GLA 1296/4885ALDH1A1 2204/4885
US-20250122212-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 KDM4E 3515/4885GLA 1774/4885ALDH1A1 515/4885
US-12473291-B2 Benzodiazepine compound, preparation method therefor, and use thereof in medicine GABRA1, GABRA4, GABRR1 KDM4E 833/4885GLA 4718/4885ALDH1A1 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.